

29. (once amended) A transformed cell having the antisense of a nucleic acid molecule of claim 1.

A copy of the amendments to the claims and a clean copy of the amended claims are attached.

REMARKS

Restriction under 35 U.S.C. 121

Claims 8, 9, 14, 15, 16, 17, 19, 20, 21, 22, 26, 27 and 30 have been cancelled without prejudice. Amended claims 1-3, and 5-16 are pending.

1. The Office has identified ten inventions as follows:

- I. Claims 1-7, 10-13, 18, 23-25, and 28-29, drawn to a nucleic acid, methods for producing and purifying a polypeptide, and host cells, classified in 435, subclass 69.1.
- II. Claims 8-9 drawn to a method of identifying a nucleic acid by hybridization using a detectably labeled nucleic acid probe, classified in 435, subclass 6.
- III. Claims 14 and 26 drawn to a purified protein, classified in class 530, subclass 350+.
- IV. Claims 15 and 27, drawn to an antibody that binds to a purified protein, classified in 530, subclass 387.1.
- V. Claims 16-17, drawn to a transgenic animal, classified in class 800, subclass 13.
- VI. Claim 19, drawn to a method of identifying a biologically active composition using a sample comprising a protein, classified in 435, subclass 7.1.
- VII. Claim 20, drawn to an undisclosed compound that is detectable using a sample comprising a protein, not classifiable.

- VIII. Claims 21 and 22, drawn to a computer-readable medium and the method of using for nucleic acid sequence analysis, classified in 702, subclass 19 or 20.
- IX. Claim 30, drawn to a diagnosis method of osteoarthritis by nucleotide homology comparison of expressed mRNA or cDNA with at least 20 nucleotides identical to nucleic acid sequence compared, classified in 435, subclass 6.
- X. Claim 31, drawn to a method of isolating a nucleic acid, classified in 435, subclass 6.

2. Applicants elect Group I, without traverse.

3. The election of Group I is without prejudice to Applicants' right to file divisional applications directed to the subject matter not contained therein.

4. The Requirement for Restriction also requires election of one sequence from SEQ NOs 1-80. Applicants elect SEQ NO 58.

To comply with Requirement for Restriction, the specification has been amended as follows:

In claim 1:

In page 85, line 5, after "consisting of SEQ NO:", "1 through SEQ NO: 82" has been deleted, and "58" inserted. The term "or" has been deleted, and "and" inserted to provide proper claim form. The term "complements thereof" has been changed to "a complement thereof" to reflect the election.

In claim 10:

In page 86, line 2, after "substantially identical", "a sequence identified in Table 1" has been deleted and "SEQ NO: 58" has been inserted.

In claim 11:

In page 86, line 4, after “1-4”, “, or 8” has been deleted.

In claim 18:

In page 86, The term “or” has been deleted, and “and” inserted to provide proper claim form. The term “complements thereof” has been changed to “a complement thereof” to reflect the election.

In claim 23:

In page 87, lines 13-14, after “consisting of SEQ NO:”, “1 through SEQ NO: 82” has been deleted, and “58” inserted. The term “or” has been deleted, and “and” inserted to provide proper claim form. The term “complements thereof” has been changed to “a complement thereof” to reflect the election.

In claim 24:

In page 87, lines 17-18, after “consisting of SEQ NO:”, “1 through SEQ NO: 82” has been deleted, and “58” inserted. The term “or” has been deleted, and “and” inserted to provide proper claim form. The term “complements thereof” has been changed to “a complement thereof” to reflect the election.

In claim 25:

In page 87, lines 21-22, after “consisting of SEQ NO:”, “1 through SEQ NO: 82” has been deleted, and “58” inserted. The term “or” has been deleted, and “and” inserted to provide proper claim form. The term “complements thereof” has been changed to “a complement thereof” to reflect the election.

In claim 29:

In page 88, line 2, “28” was deleted and replaced with “29”, as the claim was mis-numbered.

In view of the foregoing amendments, it is respectfully submitted that all claims now active in the present application are in condition for allowance. Therefore, passage of the application and claims to issue is respectfully requested.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Rachel A. Polster".

Rachel A. Polster

Registration No. 47,004

Telephone: 314-694-7354

Pharmacia Corp. Patent Dept.
Patent Department Central
800 N. Lindbergh Blvd., Mail Zone O4E
St. Louis, MO 63167

Version with markings to show changes made

1. (once amended) A nucleic acid having a nucleotide sequence selected from the group consisting of SEQ NO: [1 through SEQ NO: 82] 58, [or] and a complement[s] thereof.
10. (once amended) A substantially-purified nucleic acid having at least one 10 nucleotide region substantially identical to [a sequence identified in Table 1] SEQ NO: 58.
11. (once amended) A recombinant DNA comprising a nucleic acid according to one of claims 1-4, [or 8,] wherein the recombinant nucleic acid further comprises a promoter or partial promoter region.
18. (once amended) A composition comprising a nucleic acid as claimed in one of claims 1-3, [or] and a complement[s] thereof .
23. (once amended) A substantially-purified nucleic acid molecule which comprises a nucleic acid sequence that is identical to at least 10 nucleotides of a nucleotide sequence selected from the group consisting of SEQ NO: [1 through SEQ NO: 82] 58, [or] and a complement[s] thereof.
24. (once amended) A substantially-purified nucleic acid molecule which comprises a nucleic acid sequence that is identical to at least 50 nucleotides of a nucleotide sequence selected from the group consisting of SEQ NO: [1 through SEQ NO: 82] 58, [or] and a complement[s] thereof.
25. (once amended) A substantially-purified nucleic acid molecule which comprises a nucleic acid sequence that is identical to at least 100 nucleotides of a nucleotide sequence selected from the group

09/765,231

consisting of SEQ NO: [1 through SEQ NO: 82] 58, [or] and a
complement[s] thereof.

[28]29. (once amended) A transformed cell having the antisense of a
nucleic acid molecule of claim 1.